A Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study of Ustekinumab in Pediatric Clinical Study Participants (2 to <18 Years of Age)
Latest Information Update: 14 Oct 2024
Price :
$35 *
At a glance
- Drugs Ustekinumab (Primary)
- Indications Crohn's disease; Psoriatic arthritis; Ulcerative colitis
- Focus Adverse reactions; Therapeutic Use
- Acronyms UNITED
- Sponsors Janssen Research & Development
- 27 Feb 2024 Planned End Date changed from 31 Dec 2027 to 29 Sep 2027.
- 02 Mar 2022 Planned End Date changed from 24 Feb 2028 to 31 Dec 2027.
- 02 Feb 2022 Planned End Date changed from 31 Dec 2027 to 24 Feb 2028.